Keywords
Hepatitis B virus RNA
HBeAg
Submitted : 2023-10-23
Accepted : 2023-11-07
Published : 2023-11-22
Abstract
Objective: To investigate the disparities and associations between HBV DNA and HBV RNA in various liver disease groups with respect to HBeAg status. Methods: Between September 2020 and September 2023, 90 patients diagnosed with chronic hepatitis B (CHB), 74 patients diagnosed with liver cirrhosis (LC), and 102 patients diagnosed with hepatocellular carcinoma (HCC) from the Department of Gastroenterology or Infection at the First Affiliated Hospital of Xi’an Jiaotong University were selected. HBV DNA, HBV RNA, and HBeAg quantitative tests were conducted using serum samples from the same patients. Results: In the three groups of cases, the HBV RNA load was higher when HBeAg was positive than when HBeAg was negative, and this difference was statistically significant. Only in the HCC group was the HBV DNA load significantly higher when HBeAg was positive than when HBeAg was negative. Additionally, there was a positive correlation between HBV DNA and HBV RNA regardless of HBeAg status. Conclusion: During HBeAg conversion, HBV RNA demonstrates a more sensitive response than HBV DNA. As CHB progresses to LC or HCC, HBV RNA exhibits better diagnostic value than HBV DNA.
References
Vachon A, Osiowy C, 2021, Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. Viruses, 13(6): 951. https://doi.org/10.3390/v13060951
Stanaway JD, Flaxman AD, Naghavi M, et al., 2016, The Global Burden of Viral Hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. Lancet, 388(10049): 1081–1088. https://doi.org/10.1016/S0140-6736(16)30579-7
Tu T, Budzinska MA, Shackel NA, et al., 2017, HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses, 9(4): 75. https://doi.org/10.3390/v9040075
Padarath K, Deroubaix A, Kramvis A, 2023, The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma. Viruses, 15(4): 857. https://doi.org/10.3390/v15040857
Magnius LO, Lindholm A, Lundin P, et al., 1975, A New Antigen-Antibody System. Clinical Significance in Long-Term Carriers of Hepatitis B Surface Antigen. JAMA, 231(4): 356–359. https://doi.org/10.1001/jama.231.4.356
Jiang B, Dai Q, Liu Y, et al., 2022, Levels of HBV RNA in Chronic HBV Infected Patients During First-Line Nucleos(t)ide Analogues Therapy. Infect Agent Cancer, 17(1): 61. https://doi.org/10.1186/s13027-022-00473-9
Su Q, Wang SF, Chang TE, et al., 2001, Circulating Hepatitis B Virus Nucleic Acids in Chronic Infection: Representation of Differently Polyadenylated Viral Transcripts During Progression to Nonreplicative Stages. Clin Cancer Res, 7(7): 2005–2015.
Coffin CS, Zhou K, Terrault NA, 2019, New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology, 156(2): 355–368.e3. https://doi.org/10.1053/j.gastro.2018.11.037
Xing L, Zeng R, Huang K, et al., 2022, Fuzheng Huayu Recipe and Its Active Compounds Inhibited HBeAg Production by Promoting TOMM34 Gene Expression in HBV-Infected Hepatocytes. Front Pharmacol, 13: 907921. https://doi.org/10.3389/fphar.2022.907921
Invernizzi F, Viganò M, Grossi G, et al., 2016, The Prognosis and Management of Inactive HBV Carriers. Liver Int, 36 Suppl 1: 100–104. https://doi.org/10.1111/liv.13006
European Association For The Study Of The Liver, 2012, EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B Virus Infection. J Hepatol, 57(1): 167–185. https://doi.org/10.1016/j.jhep.2012.02.010
Chu C-M, Liaw Y-F, 2010, Hepatitis B Surface Antigen Seroclearance During Chronic HBV Infection. Antivir Ther, 15(2): 133–143. https://doi.org/10.3851/IMP1497
Raffetti E, Fattovich G, Donato F, 2016, Incidence of Hepatocellular Carcinoma in Untreated Subjects with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Liver Int, 36(9): 1239–1251. https://doi.org/10.1111/liv.13142
Wang J, Yu Y, Li G, et al., 2018, Natural History of Serum HBV-RNA in Chronic HBV Infection. J Viral Hepat, 25(9): 1038–1047. https://doi.org/10.1111/jvh.12908
Hudu SA, Niazlin MT, Nordin SA, et al., 2018, Quantitative Hepatitis B e Antigen: A Better Predictor of Hepatitis B Virus DNA than Quantitative Hepatitis B Surface Antigen. Clin Lab, 64(4): 443–449. https://doi.org/10.7754/Clin.Lab.2017.170916
Terrault NA, Bzowej NH, Chang K-M, et al., 2016, AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology, 63(1): 261–283. https://doi.org/10.1002/hep.28156
Lok AS, Hadziyannis SJ, Weller IV, et al., 1984, Contribution of Low Level HBV Replication to Continuing Inflammatory Activity in Patients with Anti-Hbe Positive Chronic Hepatitis B Virus Infection. Gut, 25(11): 1283–1287. https://doi.org/10.1136/gut.25.11.1283
Wu Y, Wen J, Tang G, et al., 2021, On-Treatment HBV RNA Dynamic Predicts Entecavir-Induced HBeAg Seroconversion in Children with Chronic Hepatitis B. J Infect, 83(5): 594–600. https://doi.org/10.1016/j.jinf.2021.08.044
Butler EK, Gersch J, McNamara A, et al., 2018, Hepatitis B Virus Serum DNA and RNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection. Hepatology, 68(6): 2106–2117. https://doi.org/10.1002/hep.30082